Healio

Split-face study finds no difference between neurotoxins for glabellar lines

Please provide your email address to receive an email when new articles are posted on . A split-face comparison found no difference between onabotulinumtoxinA and prabotulinumtoxinA for the treatment ...
Monthly Prescribing Reference

Letybo Approved to Treat Moderate to Severe Glabellar Lines

The potency units of Letybo are not interchangeable with other preparations of botulinum toxin products. The Food and Drug Administration (FDA) has approved Letybo (letibotulinumtoxinA-wlbg) for the ...
Healio

Repeated Botox treatments improve glabellar lines at rest

Patients with mild glabellar lines at rest achieved elimination of the resting lines following repeated Botox treatment, according to recently published study results. Alastair Carruthers, MD, of the ...
Business Wire

Data from Merz Aesthetics’ Post-Market Clinical Study of Xeomin ® (incobotulinumtoxinA) vs. Botox ® (onabotulinumtoxinA) for Glabellar Facial Lines Published in ...

“ Dermatologic Surgery ’s publication of this new clinical data demonstrating the efficacy of Xeomin ® (incobotulinumtoxinA) will prove critical in encouraging physicians to consider Xeomin ® ...
Business Wire

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States ...
Yahoo Finance

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...
Nasdaq

FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States ...